Potassium-wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome.
A patient with a potassium wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome is described. A 64-year-old woman with diffuse histiocytic lymphoma developed persistent hypokalemia following a course of Cytoxan (cyclophosphamide), Adriamycin (doxorubicin), vincristine, and prednisone (CHOP)-Bleo. The diagnosis of a functional Bartter's syndrome was concluded following evaluation of serial plasma renins, aldosterone levels, and urinary electrolytes. Evidence is suggestive that a subpopulation of patients receiving chemotherapy may develop a functional Bartter's syndrome, and it is important to consider this diagnosis in patients who develop hypokalemia subsequent to chemotherapy introduction.
D000450:Aldosterone / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001477:Bartter Syndrome / Q000097:blood / Q000139:chemically induced* / Q000652:urine; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000139:chemically induced*; D007008:Hypokalemia / Q000097:blood / Q000139:chemically induced* / Q000652:urine; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000188:drug therapy / Q000652:urine; D008274:Magnesium / Q000652:urine; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012083:Renin / Q000097:blood; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D001761:Bleomycin; D000450:Aldosterone; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D012083:Renin; D008274:Magnesium; D011241:Prednisone